Amgen's Novel Weight Loss Drug Shows Potential for Longer Lasting Effect With Less Frequent Dosing Than Wegovy, Zepbound

In a Phase I trial, data suggest that Amgen’s maridebart cafraglutide (MariTide) may allow patients to take lower and less frequent doses over time while still maintaining significant weight loss.